1. An isolated antibody that binds to PMEL17, characterized in that the antibody binds an epitope within amino acids 105-125 sequences SEQ ID № 26 or binds an epitope within amino acids 25-45 sequence SEQ ID № 26.2. An antibody according to Claim. 1 which is a monoclonal antitelom.3. An antibody according to Claim. 1 which is a human, humanized or chimeric antitelom.4. An antibody according to Claim. 1 which is an antibody fragment that binds PMEL17.5. An antibody according to claim. 1, characterized in that PMEL17 is PMEL17 cheloveka.6. An antibody according to claim. 5, characterized in that PMEL17 human sequence comprises SEQ ID № 26 or SEQ ID № 27.7. The antibody of claim 1, wherein the antibody comprises:. A) (i) HVR-H3, comprising the amino acid sequence of SEQ ID № 5, (ii) HVR-L3, comprising the amino acid sequence of SEQ ID № 8, and (iii) HVR -H2, comprising the amino acid sequence of SEQ ID № 4 or b) (i) HVR-H3, comprising the amino acid sequence of SEQ ID №15, (ii) HVR-L3, comprising the amino acid sequence of SEQ ID № 8, and (iii) HVR-H2, having the amino acid sequence of SEQ ID № 14 ilic) HVR-H3, HVR-L3, and HVR-H2 antibody, synthesized by the hybridoma 7509 (31D1.6.7), having ATCC accession number PTA-№ 12862.8. The antibody of claim 1, wherein the antibody comprises:. A) (i) HVR-H1, comprising the amino acid sequence of SEQ ID № 3, (ii) HVR-H2, having the amino acid sequence of SEQ ID № 4, and (iii) HVR -H3, comprising the amino acid sequence of SEQ ID № 5 or b) (i) HVR-H1, comprising the amino acid sequence of SEQ ID № 13, (ii) HVR-H2, having the amino acid sequence of SEQ ID № 14, and (iii) HVR-H3, comprising the amino acid sequence of SEQ ID № 15 ilic) HVR-H1, HVR-H2 and HVR-H3 antibody, synthesized by the hybridoma 7509 (31D1.6.7), having ATCC accession number PTA-№ 12862.9. An antibody according to claim 8, characterized in that the antibody comprises:. A) (i) HVR-H1, comprising the amino acid sequence of SEQ ID № 3, (ii) HVR-H2, comprising
